Artwork

Innhold levert av Liberum IME. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Liberum IME eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Immunotherapy series | Consensus best practice approaches to metastatic head and neck squamous cell carcinoma (HNSCC)

18:30
 
Del
 

Manage episode 317722617 series 3304844
Innhold levert av Liberum IME. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Liberum IME eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Immune checkpoint inhibitors are a relatively new treatment option for patients with metastatic, unresectable head and neck squamous cell carcinoma (HNSCC), and so they have not yet been incorporated into clinical practice guidelines. For this reason, we interview Professor Frederic Peyrade, Head of Clinical Research and Professor of Oncology, Antoine Lacassagne Cancer Centre, France, to get expert advice on incorporating immune checkpoint inhibitors into current treatment protocols.

References

- Grégoire V, et al. Ann Oncol. 2009; 20 Suppl 4: 121-2

- Dimitrios Colevas, et al. J Natl Compr Canc Netw. 2018 May; 16(5): 479-490

- Cohen, et al. J Immunother Cancer. 2019 Jul 15; 7(1): 184

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.

  continue reading

32 episoder

Artwork
iconDel
 
Manage episode 317722617 series 3304844
Innhold levert av Liberum IME. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Liberum IME eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Immune checkpoint inhibitors are a relatively new treatment option for patients with metastatic, unresectable head and neck squamous cell carcinoma (HNSCC), and so they have not yet been incorporated into clinical practice guidelines. For this reason, we interview Professor Frederic Peyrade, Head of Clinical Research and Professor of Oncology, Antoine Lacassagne Cancer Centre, France, to get expert advice on incorporating immune checkpoint inhibitors into current treatment protocols.

References

- Grégoire V, et al. Ann Oncol. 2009; 20 Suppl 4: 121-2

- Dimitrios Colevas, et al. J Natl Compr Canc Netw. 2018 May; 16(5): 479-490

- Cohen, et al. J Immunother Cancer. 2019 Jul 15; 7(1): 184

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.

  continue reading

32 episoder

All episodes

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2025 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett
Lytt til dette showet mens du utforsker
Spill